Vision

The testing for endothelial dysfunction – a key marker of cardiovascular disease – is changing the way physicians diagnose and monitor the disease. This paradigm shift in medical practice has created a market for endothelial dysfunction testing. The size of this new market is poised to rival that of the market for blood pressure monitoring. Angiologix, with its accurate, non-invasive, point-of-care diagnostic products for the detection of endothelial dysfunction, will capitalize on this emergent and rapidly-growing market.

The current cardiovascular diagnostic tools assess risk factors (high blood pressure, elevated cholesterol levels, etc.) and detect atherosclerotic plaque (by coronary angiography, stress testing, etc.). However, the diagnosis of the risk factors in a patient provides no information about the early pathological changes in his blood vessels; and, by the time atherosclerotic plaque is detected, the disease is already well advanced. No diagnostic tool is available for early detection of the blood vessel damage which leads up to the formation of atherosclerotic plaque. As a result, millions of patients are not being treated at the early stages of the disease when medical interventions are most effective. A substantial unmet need exists for better diagnostics of the early-stage cardiovascular disease. Endothelial dysfunction is one of the earliest pathological changes in the blood vessels and has emerged as a key marker of early-stage cardiovascular disease. Endothelial dysfunction is a crucial and reversible step in the development of the disease. The exceptional clinical value of this key marker has been proven for detecting early cardiovascular disease, for monitoring the disease’s progression and for predicting future cardiovascular events such as heart attack and stroke. However, the current diagnostic tests of endothelial dysfunction are unsuited for widespread point-of-care use. A tremendous business opportunity exists for a maker of accurate, easy-to-use, noninvasive tests for the diagnosis of endothelial dysfunction.